HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

HER2-Positive Patients Benefit From Combination Therapy of Trastuzumab and Lapatinib

January 17th 2012

Two new studies suggest that dual inhibition of HER2 might serve as a better approach to treating patients with HER2-positive breast cancer.

Exploiting Oncogene Addiction and Immunogenicity May Be Path to Improved Results in HER2-Positive Breast Cancer

December 27th 2011

The approval of trastuzumab, targeted directly to the human epidermal growth factor receptor (HER2)-positive, was a major advance in extending the lives of women with HER2-positive breast cancer.

Efforts to Improve HER2 Testing Continue ASCO Panelist Sees Progress

October 11th 2011

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

Effectiveness of Adriamycin Questioned in the Treatment of Patients With HER2-Positive Breast Cancer

October 7th 2011

HER2-positive women can be effectively treated with Herceptin (trastuzumab injection) without the use of Adriamycin.

T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer

September 25th 2011

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

Dr. Dixon on Systemic Advances in Breast Cancer

September 13th 2011

Dr. J. Michael Dixon from University of Edinburgh on Advances in Breast Cancer Systemic Therapy

Dr. Wolff Discusses the Importance of HER2 Testing

August 15th 2011

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.

HER2 Signaling Beckons: Dimerization Process, Combination Therapies Highlight New Research

June 24th 2011

The first drug that successfully targeted the HER2 pathway in cancer treatment generated much excitement.

New Genetic Test Aids Detection of HER2+ Breast Cancer

June 15th 2011

On Tuesday the FDA approved a genetic test known as Inform Dual ISH that detects HER2+ breast cancer

Rethinking Initial Management of Patients With Brain Metastasis and HER2 Breast Cancer

June 6th 2011

Lapatinib and capecitabine is a reasonable approach in a well-informed patient with brain metastasis and HER2+ breast cancer

Shedding More Light on Identifying HER2

March 16th 2011

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

March 4th 2011

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

SABCS Coverage: Trastuzumab Superior to Lapatinib in HER2-Positive Breast Cancer, But Combination Is Best

March 2nd 2011

Two trials explored the role of lapatinib (Tykerb) as neoadjuvant therapy in early-stage HER2-positive breast cancer and concluded that its effectiveness is statistically no better than standard trastuzumab (Herceptin) therapy

ASCO GI Coverage: Australian Study Finds ISH to Be the Best Assessor of HER2 Expression in Gastric Cancer

March 2nd 2011

In situ hybridization (ISH) yields the best results for assessing HER2 expression in gastric cancer, according to a multilaboratory analysis of testing methods.

Beyond Genetics: Emerging Breakthroughs in Breast Cancer Battle

November 17th 2008

Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.